BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20261028T160000
DTEND;TZID=Europe/Stockholm:20261028T170000
DTSTAMP:20261009T170812
CREATED:20261009T120435Z
LAST-MODIFIED:20261009T121141Z
UID:37548-1793203200-1793206800@senzagen.com
SUMMARY:Webinar: Advancing Medical Device Biocompatibility testing with NAMs
DESCRIPTION:Regulatory updates and industry case studies\nCan the “Big Three” be addressed using non-animal methods? Scientifically validated in vitro approaches are available to assess cytotoxicity\, skin irritation and skin sensitization\, supporting more predictive and human-relevant biocompatibility testing. As the regulatory landscape continues to evolve\, medical device manufacturers face growing opportunities to incorporate these methods into biocompatibility assessments and regulatory submissions. \nJoin us for a webinar exploring the latest developments within the ISO 10993 framework and how New Approach Methodologies (NAMs) are being applied in practice. Through regulatory perspectives and industry case studies\, our speakers will discuss how in vitro methods can support decision-making from early material screening to CE-marking submissions. \nBuild readiness\n• Develop your NAM database\n• Gain testing experience\n• Strengthen weight-of-evidence assessments \n  \n \nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, register anyway to receive the recording. \nKey takeaways\n\nRegulatory insights: Stay informed on the latest developments in ISO 10993-5\, ISO 10993-23 and ISO 10993-10\, and the growing role of in vitro methods. \nGARD® advancements: Learn how GARD® supports both skin sensitization hazard and quantitative potency assessment of extractable medical devices and solid materials in polar and non-polar vehicles. \nIndustry application: Discover how NAMs are used as weight-of-evidence in CE-marking submissions\, testing of 3D-printed oral devices\, metallic 3D-printing materials\, and early-stage material screening.\n\nSpeaker\n \nAndy Forreryd\, PhD\nScientific Liaison Manager @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 on irritation and sensitization.\nMember of OECD expert group on respiratory sensitization.\n\n Additional speakers to be announced \n \n  \n\n 
URL:https://senzagen.com/event/webinar-medical-device-biocompatibility-testing-2026/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
END:VCALENDAR